Biomarkers are being explored for their potential to detect and monitor drug-induced kidney injury in clinical trials. Research has identified several biomarkers, including urinary clusterin, that may allow for earlier detection of kidney injury and response to treatment. The development and qualification of these biomarkers could potentially transform kidney injury monitoring and treatment, with some studies suggesting they may have significant impact on drug development.